Page last updated: 2024-11-02

pentoxifylline and Hepatic Encephalopathy

pentoxifylline has been researched along with Hepatic Encephalopathy in 4 studies

Hepatic Encephalopathy: A syndrome characterized by central nervous system dysfunction in association with LIVER FAILURE, including portal-systemic shunts. Clinical features include lethargy and CONFUSION (frequently progressing to COMA); ASTERIXIS; NYSTAGMUS, PATHOLOGIC; brisk oculovestibular reflexes; decorticate and decerebrate posturing; MUSCLE SPASTICITY; and bilateral extensor plantar reflexes (see REFLEX, BABINSKI). ELECTROENCEPHALOGRAPHY may demonstrate triphasic waves. (From Adams et al., Principles of Neurology, 6th ed, pp1117-20; Plum & Posner, Diagnosis of Stupor and Coma, 3rd ed, p222-5)

Research Excerpts

ExcerptRelevanceReference
"Serum levels of liver enzymes, blood ammonia and prothrombin time and the stage of hepatic encephalopathy were significantly improved in rats treated with dimethylsulfoxide or dimethylthiourea compared to the other treatment groups (p<0."3.70The hydroxyl radical scavengers dimethylsulfoxide and dimethylthiourea protect rats against thioacetamide-induced fulminant hepatic failure. ( Aeed, H; Avni, Y; Bruck, R; Halpern, Z; Matas, Z; Shirin, H; Zaidel, L, 1999)
"Treatment with pentoxifylline was the only factor associated with liver-related complications."2.75Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. ( Barraud, H; Carbonell, N; Condat, B; Lebrec, D; Moreau, R; Oberti, F; Perarnau, JM; Poynard, T; Ramond, MJ; Renard, P; Saliba, F; Thabut, D, 2010)
"Severe alcoholic hepatitis (SAH) is defined by modified Maddrey discriminant function ≥32 or Model for End-Stage Liver Disease (MELD) >21 and/or hepatic encephalopathy."2.55New paradigms in management of alcoholic hepatitis: a review. ( Goyal, O; Kishore, H; Sidhu, S; Sidhu, SS, 2017)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (25.00)18.2507
2000's1 (25.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sidhu, SS1
Goyal, O1
Kishore, H1
Sidhu, S1
Lebrec, D1
Thabut, D1
Oberti, F1
Perarnau, JM1
Condat, B1
Barraud, H1
Saliba, F1
Carbonell, N1
Renard, P1
Ramond, MJ1
Moreau, R1
Poynard, T1
Bruck, R1
Aeed, H1
Shirin, H1
Matas, Z1
Zaidel, L1
Avni, Y1
Halpern, Z1
Koczorek, M1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Clinical Trial of Pentoxifylline Administration Versus Placebo on Survival in Patients With Cirrhosis and Severe Liver Failure[NCT00162552]Phase 3342 participants (Actual)Interventional2004-08-31Completed
A Phase II Trial of Pentoxifylline in Newly-Diagnosed Biliary Atresia[NCT01774487]Phase 217 participants (Actual)Interventional2013-02-04Terminated (stopped due to Target enrollment was not reached because the medication, pentoxifylline, has a taste that is not well tolerated by infants. The study team decided to end the study before meeting the enrollment goal because of the medication taste.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Alanine Amino Transferase (ALT) Levels at 2 Years of Life

The investigators will record the ALT levels at age two years, in patients who had previously been treated with PTX therapy and still have their native liver. Scale 14-45 U/L, with a higher level indicating a worse outcome. (NCT01774487)
Timeframe: 2 years of age

InterventionU/L (Mean)
Pentoxifylline - Group 1160

Number of Participants Achieving Zero or Positive Weight Z-scores 12 Weeks After Starting PTX Therapy

The investigators will track the weight of patients over the course of therapy in patients receiving 90 days of PTX (this is recorded as part of routine clinical care). The weight will then be compared to standards to calculate a z-score. Normal weight Z-score is greater than or equal to 0, with a higher number of patients meeting this indicating a better outcome. (NCT01774487)
Timeframe: 12 weeks after starting therapy

InterventionParticipants (Count of Participants)
Pentoxifylline - Group 10
Group 20

Number of Participants With Normal Serum Conjugated Bilirubin Levels 12 Weeks After Starting PTX (Pentoxifylline) Therapy

The investigators will track the serum conjugated bilirubin (CB) levels over the course of therapy in patients receiving 90 days of PTX (this laboratory test is drawn as part of routine care). Normal CB is 0.0-0.3 mg/dL, with a higher number of patients meeting this indicating a better outcome. (NCT01774487)
Timeframe: 12 weeks after starting therapy

InterventionParticipants (Count of Participants)
Pentoxifylline - Group 16
Pentoxifylline - Group 20

Platelet Levels at 2 Years of Life

The investigators will record platelet levels at age two years, in patients who had previously been treated with PTX therapy and still have their native liver. Scale 189-403*10^3 Platelets/μL, with a lower level indicating a worse outcome. (NCT01774487)
Timeframe: 2 years of age

Intervention10^3 Platelets/μL (Mean)
Pentoxifylline - Group 1208

Spleen Size at 2 Years of Age

"The investigators will measure spleen size by ultrasound at 2 years of age, in patients who had received PTX therapy earlier and still have their native liver. Normal spleen size range (10th-90th percentile) at this age is 6.4-8.6 cm, with a value exceeding this range indicating a worse outcome." (NCT01774487)
Timeframe: 2 years of age

Interventioncm (Mean)
Pentoxifylline - Group 110.0

Time to Liver Transplant

The investigators will track time to liver transplant. The shorter time to liver transplant indicates a worse outcome. (NCT01774487)
Timeframe: Baseline and up to two years after therapy finishes

Interventiondays (Mean)
Pentoxifylline - Group 1317
Pentoxifylline - Group 2273

Reviews

1 review available for pentoxifylline and Hepatic Encephalopathy

ArticleYear
New paradigms in management of alcoholic hepatitis: a review.
    Hepatology international, 2017, Volume: 11, Issue:3

    Topics: Adrenal Cortex Hormones; Animals; Anti-Inflammatory Agents; Fecal Microbiota Transplantation; Female

2017

Trials

1 trial available for pentoxifylline and Hepatic Encephalopathy

ArticleYear
Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis.
    Gastroenterology, 2010, Volume: 138, Issue:5

    Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Double-Blind Method; France; Gastrointestin

2010
Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis.
    Gastroenterology, 2010, Volume: 138, Issue:5

    Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Double-Blind Method; France; Gastrointestin

2010
Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis.
    Gastroenterology, 2010, Volume: 138, Issue:5

    Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Double-Blind Method; France; Gastrointestin

2010
Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis.
    Gastroenterology, 2010, Volume: 138, Issue:5

    Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Double-Blind Method; France; Gastrointestin

2010

Other Studies

2 other studies available for pentoxifylline and Hepatic Encephalopathy

ArticleYear
The hydroxyl radical scavengers dimethylsulfoxide and dimethylthiourea protect rats against thioacetamide-induced fulminant hepatic failure.
    Journal of hepatology, 1999, Volume: 31, Issue:1

    Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Dimethyl Sulfoxide; Free Radical Scaveng

1999
[Chronic liver diseases. The nihilism has gone].
    MMW Fortschritte der Medizin, 2001, Dec-13, Volume: 143, Issue:51-52

    Topics: Amantadine; Antioxidants; Antiviral Agents; Chronic Disease; Dipeptides; Drug Therapy, Combination;

2001